Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Eugenio Mercuri

Professor of Pediatric Neurology

Università Cattolica del Sacro Cuore

Italy

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

70%

Neurology

50%

Muscular Atrophy

70%

Medical Therapy

30%

Neuroprotection

30%

Drug Formulation

20%

Neurodegenerative Disease

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles18

Single Nucleotide SMN1 Variants in a Cohort of Individuals With Spinal Muscular Atrophy

Article Link

Year:

2025

Expressive language and social communication abilities in children with spinal muscular atrophy type 1

Article Link

Year:

2025

Corticosteroid therapy in Duchenne muscular dystrophy: Management and new insights

Article Link

Year:

2025

Pregnancy in the Era of Disease‐Modifying Therapies for Spinal Muscular Atrophy: Considerations From a Case Report

Article Link

Year:

2025

Italian survey on evolving SMA care with disease-modifying therapies: a consensus workshop on nutrition, swallowing, respiratory and rehabilitation care

Article Link

Year:

2025

Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy

Article Link

Year:

2025

JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam

Article Link

Year:

2024

Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy

Article Link

Year:

2024

Towards harmonization of clinical tools for assessing Brain Involvement in Dystrophinopathies (BIND); report of four expert workshops: Newcastle, Leiden, Rome, Paris

Article Link

Year:

2024

Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment

Article Link

Year:

2023

New therapies for spinal muscular atrophy: where we stand and what is next

Article Link

Year:

2023

Scientific rationale for a higher dose of nusinersen

Article Link

Year:

2022

Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era

Article Link

Year:

2021

Reply to: The need for evidence‐based treatment decisions in spinal muscular atrophy type 0

Article Link

Year:

2021

Spinal muscular atrophy: from rags to riches

Article Link

Year:

2021

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy

Article Link

Year:

2021

Nusinersen in type 0 spinal muscular atrophy: should we treat?

Article Link

Year:

2020

Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019

Article Link

Year:

2020

Collaborators9

Antonio G. deBelvis

Università Cattolica del Sacro Cuore

ITALY

Anna Kostera-Pruszczyk

Head of Department/Prof.

Medical University of Warsaw

POLAND

francesco danilo tiziano

Associate professor

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia

ITALY

Giovanni Baranello

Prof.

University College London

UNITED KINGDOM

Gabriele Siciliano

Full Professor

University of Pisa

ITALY

Piero Valentini

Università Cattolica del Sacro Cuore

ITALY

odile boespflug-tanguy

Professor

Université Paris Diderot

FRANCE

Lorenzo Fontanelli

University of Pisa

ITALY

Tina Duong

Stanford University

UNITED STATES

How do I reach out?

Meet Kite AI